Articles tagged "Rejection"

2021 American Transplant Congress
Titer Stability vs. Terminal Pre-transplant Titer: Titer History is Irrelevant for A₂ to B Transplantation
A. Gilbert¹, S. Radomski², J. Vucci¹, B. Thomas¹, M. Cooper¹
¹Medstar Georgetown Transplant Institute, Washington, DC, ²Johns Hopkins Medical Center, Baltimore, MD
*Purpose: Minor ABO incompatibile (ABOi) transplants from blood group A2 or A2B donors have increased since 2014, but initial guidance suggested that establishing an anti-A…
2021 American Transplant Congress
Longitudinal Studies of Blood Anellovirus DNA Prior to Acute Rejection or Major Infection Events in Pediatric Kidney Transplant Recipients (PKTx)
R. Dandamudi, H. Gu, C. Goss, H. Gula, K. Wylie, V. Dharnidharka
Washington University in St Louis, St. Louis, MO
*Purpose: Blood levels of the ubiquitous but non-pathogenic anellovirus (AnV) taxa have been postulated to represent a biomarker of the overall state of immunosuppression after…
2021 American Transplant Congress
Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Rejection After Change in Maintenance Immunosuppression Regimens in the First Year Post Kidney Transplant
M. Walsh, V. Peev, L. Lineberger, M. Brokhof, N. Kenyon, N. Alvey
Rush University Medical Center, Chicago, IL
*Purpose: The purpose of this study was to investigate whether the use of donor-derived cell-free DNA (dd-cfDNA) is an effective screening tool for allograft rejection…
2021 American Transplant Congress
Antibody-mediated Rejection and Sponge Effect in a Redo Lung Transplant Recipient: A Case Report
A. Arjuna, M. T. Olson, S. Tokman, R. Walia, T. Mohanakumar, A. S. Hashimi, M. A. Smith, R. M. Bremner, A. Omar
Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ
*Purpose: Antibody-mediated rejection (AMR) typically presents with elevated titers of circulating donor specific antibodies (DSA) and increased mean fluorescence intensity (MFI), a surrogate marker for…
2020 American Transplant Congress
C-Reactive Protein 1-Year Post-Transplant is Associated with Future Development of Coronary Artery Vasculopathy and Rejection in a Pediatric Heart Transplant Cohort
H. J. Tadros, A. H. Bashir, F. J. Fricker, B. A. Pietra, D. Gupta
Congenital Heart Center/Pediatrics, University of Florida, Gainesville, FL
*Purpose: Coronary artery vasculopathy (CAV) is one of the leading causes of mortality beyond 3y post-transplant (OHT). Multiple risk factors are associated with development of…
2020 American Transplant Congress
Prospective Donor-Specific CellUlar Alloresponse Assessment for Immunosuppression MinImization in De Novo Renal Transplantation: Results of a Randomized Controlled Biomarker-Guided Trial
O. Bestard¹, P. Reinke², F. Bemelman³, O. Viklicky⁴, M. Koch⁵, M. Giral⁶, J. Ruiz⁷, B. Banas⁸, E. Crespo¹, M. Meneghini¹, H. Volk⁹, J. Grinyo¹
¹Kidney transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, ²Kidney transplantation Unit, Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Kidney transplantation Unit, Amsterdam Medical Centre, Amsterdam, Netherlands, ⁴Nephrology department, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic, ⁵Department of Hepatobiliary Surgery and Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁶Nephrology, Kidney transplantation Unit, Université de Nantes, Nantes, France, ⁷Nephrology, Hospital Marques de Valdecilla, Santander, Spain, ⁸Kidney transplantation Unit, University Hospital Regensburg, Regensburg, Germany, ⁹Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
*Purpose: Early immunosuppression minimization is associated with higher rates of BPAR. Preformed donor-specific T-cell alloreactivity (DST) assessed with an IFN-γ ELISPOT assay has shown to…
2020 American Transplant Congress
ATHENA – Patient and Allograft Outcome Differences after Kidney Transplantation – Germany vs. France
F. Thaiss¹, C. Sommerer¹, B. Suwelack¹, D. Dragun¹, I. A. Hauser¹, O. Witzke¹, C. Hugo¹, P. Schenker¹, N. Kamar², P. Merville², I. Kroeger³, M. Junge³, B. Nashan¹
¹Athena, Study Group, Germany, ²Athena, Study Group, France, ³Novartis Pharma GmbH, Nürnberg, Germany
*Purpose: In the ATHENA trial [NCT01843348], efficacy and safety of everolimus in combination with tacrolimus [EVR+TAC] or cyclosporine A [EVR+CyA] vs. TAC and mycophenolic acid…
2020 American Transplant Congress
HLA Molecular Mismatch is an Independent Correlate of T-Cell Mediated Rejection and Potential Prognostic Biomarker in Renal Transplantation
C. Wiebe¹, D. Pochinco², I. W. Gibson³, J. Ho¹, P. Birk⁴, A. Goldberg⁴, M. Karpinski⁵, J. Shaw⁵, R. N. David⁵, P. W. Nickerson¹
¹Medicine and Immunology, University of Manitoba, Winnipeg, MB, Canada, ²Shared Health Services, Winnipeg, MB, Canada, ³Pathology, University of Manitoba, Winnipeg, MB, Canada, ⁴Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada, ⁵Medicine, University of Manitoba, Winnipeg, MB, Canada
*Purpose: HLA molecular mismatch alloimmune risk categorization has correlated with de novo donor-specific antibody (dnDSA) development, however, correlation with T-cell mediated rejection (TCMR) phenotypes is…
2020 American Transplant Congress
Clinical Significance of C4d and HLA-DSA on Post-Transplant Clinical Outcomes in Kidney Transplant Recipients with Antibody-Mediated Rejection
W. Park, O. Kwon, Y. Kim, J. Paek, K. Jin, S. Park, S. Han
Internal Medicine, Keimyung University School of Medicine, Keimyung University Kidney Institute, Daegu, Korea, Republic of
*Purpose: The clinicopathological diagnosis of rejection after kidney transplantation (KT) was well defined by Banff classification. In the diagnosis of antibody-mediated rejection (AMR), the presence…
2020 American Transplant Congress
Single versus Dual Immunosuppression in Liver Transplantation for Autoimmune Liver Diseases
S. Sterling¹, S. Hamel¹, C. Garza¹, I. Feurer², S. Rega², S. Alexopoulos³, M. Izzy⁴
¹Pharmacy, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt Transplant Center, Nashville, TN, ³Liver Transplant Surgery, Vanderbilt Transplant Center, Nashville, TN, ⁴Transplant Hepatology, Vanderbilt Transplant Center, Nashville, TN
*Purpose: There is limited evidence on the optimal maintenance immunosuppression after liver transplant (LT) for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune…